Commerce Bank Has $82.67 Million Stock Position in Danaher Co. (NYSE:DHR)

Commerce Bank decreased its position in Danaher Co. (NYSE:DHR) by 0.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 357,369 shares of the conglomerate’s stock after selling 2,261 shares during the period. Commerce Bank’s holdings in Danaher were worth $82,674,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the business. BKM Wealth Management LLC bought a new position in shares of Danaher during the 4th quarter valued at about $27,000. Wetzel Investment Advisors Inc. bought a new stake in shares of Danaher in the fourth quarter worth $29,000. Rakuten Securities Inc. acquired a new position in Danaher during the fourth quarter worth $36,000. Financial Connections Group Inc. bought a new position in Danaher in the fourth quarter valued at $41,000. Finally, Frazier Financial Advisors LLC bought a new stake in Danaher during the 4th quarter worth about $44,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. Raymond James boosted their price target on Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 31st. KeyCorp raised their price objective on Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, February 1st. Robert W. Baird increased their price target on Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a research note on Wednesday, April 24th. Barclays increased their price objective on shares of Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 24th. Finally, StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Six analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $267.31.

Danaher Price Performance

Shares of DHR stock traded down $5.62 during trading hours on Thursday, reaching $261.57. The company’s stock had a trading volume of 1,783,775 shares, compared to its average volume of 2,686,670. The company has a quick ratio of 1.51, a current ratio of 1.85 and a debt-to-equity ratio of 0.31. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $268.98. The company has a market capitalization of $193.74 billion, a price-to-earnings ratio of 45.31, a PEG ratio of 4.08 and a beta of 0.83. The firm’s 50 day simple moving average is $249.54 and its 200-day simple moving average is $238.04.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. The firm had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.62 billion. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The business’s revenue for the quarter was down 2.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.36 earnings per share. Sell-side analysts forecast that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be given a $0.27 dividend. The ex-dividend date of this dividend is Friday, June 28th. This represents a $1.08 dividend on an annualized basis and a yield of 0.41%. Danaher’s dividend payout ratio is currently 18.31%.

Insiders Place Their Bets

In other news, CEO Rainer Blair sold 9,005 shares of Danaher stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $265.00, for a total transaction of $2,386,325.00. Following the sale, the chief executive officer now directly owns 106,990 shares of the company’s stock, valued at $28,352,350. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Danaher news, CEO Rainer Blair sold 9,005 shares of the company’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $265.00, for a total transaction of $2,386,325.00. Following the sale, the chief executive officer now owns 106,990 shares of the company’s stock, valued at $28,352,350. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Matthew Mcgrew sold 46,377 shares of Danaher stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $253.05, for a total value of $11,735,699.85. Following the completion of the transaction, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at $7,441,441.35. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 172,540 shares of company stock valued at $43,523,481. 11.10% of the stock is currently owned by insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.